Stock ANRO ALTO NEUROSCIENCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Alto Neuroscience, Inc.

Equities

ANRO

US02157Q1094

Market Closed - Nyse
Other stock markets
 21:00:02 25/06/2024 BST 		5-day change 1st Jan Change
9.84 USD -5.93% Intraday chart for Alto Neuroscience, Inc. -11.75% 0.00%
06-24 Alto Neuroscience, Inc.(NYSE:ANRO) added to S&P Global BMI Index CI
06-20 Alto Neuroscience, Inc. Initiates Phase 2 Study of ALTO-101, Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alto Neuroscience, Inc.(NYSE:ANRO) added to S&P Global BMI Index
CI
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
BU
Alto Neuroscience, Inc. Initiates Phase 2 Study of ALTO-101, Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
CI
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur of the Year 2024 Bay Area Award Winner
AQ
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
BU
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
BU
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
BU
Alto Neuroscience, Inc. Appoints Michael Hanley as Chief Operating Officer
CI
Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
BU
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
BU
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
BU
Alto Neuroscience, Inc. Announces Positive Phase 1 Results for ALTO-101, A Novel PDE4 Inhibitor in Development for Schizophrenia
CI
Alto Neuroscience Starts Phase 2 Trial of ALTO-203 in Major Depressive Disorder Patients
MT
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
BU
Alto Neuroscience, Inc. Announces Initiation of Phase 2 Study of Alto-203 in Patients with Major Depressive Disorder
CI
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
BU
Alto Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Alto Neuroscience, Inc.(NYSE:ANRO) added to S&P TMI Index
CI
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANRO Stock
  4. News Alto Neuroscience, Inc.